Idiopathic pulmonary fibrosis (IPF) is the most common and devastating form of idiopathic interstitial pneumonia. It generally affects elderly males with a history of smoking, and there are only two Food and Drug Administration-approved therapeutic options for this disease. Despite these groundbreaking drugs, improvements in patient-centered outcomes are lacking, and patients and providers alike are desperately seeking additional treatment options (1) (2) (3) . The full extent of the pathogenesis leading to the progressive fibrotic nature of IPF is yet unknown. It is evident that several cellular and molecular pathways exist and may be necessary for the development of clinical pulmonary fibrosis (4). Defining these aberrant pathways is a crucial first step in developing therapeutic interventions that act by inhibiting key enzymes and intermediaries.
The study by Cui and colleagues (pp. 492-500) in this issue of the Journal (5) builds upon their preceding novel work that described a proposed mechanistic pathway of collagen expression mediated by products of glutaminolysis (6) . This pathway is responsible for converting glutamine to glutamate, thereby replenishing the tricarboxylic acid cycle by production of a-ketoglutarate. This conversion depends on the enzyme glutaminase (Gls). The authors previously asserted that the a-ketoglutarate is implicated to have downstream effects, causing increased proline hydroxylation and mTOR complex 1 activation (6). These processes have been shown to play important roles in intracellular collagen stabilization and collage synthesis, respectively. In their seminal work, the authors demonstrated that the Gls1 isoform is present, and most active, in human lung fibroblasts. Collagens, along with extracellular matrix proteins, form the pathological pulmonary scar tissue that is a hallmark of IPF. The authors also posited that disruption of this pathway with the known Gls1 inhibitor CB-839 can serve as a basis for successful therapeutic intervention, similar to what was reported in associated preclinical studies in cancer (7, 8) .
In the present study, the authors evaluated the glutaminolysis process in two accepted pulmonary fibrosis mouse models. First, they sought to replicate their prior human study and demonstrate that Gls1 is upregulated in a pulmonary fibrosis mouse model. They created a mouse strain with labeled fibroblasts and exposed the mice to either saline or bleomycin for 3 weeks. They demonstrated increased expression of Gls1 in mouse lungs that were exposed to bleomycin compared with saline-treated lungs. Next, they evaluated Gls1 expression in a pulmonary fibrosis mouse model that was induced by exposure to transforming growth factor b (TGF-b), and again found increased transcription and protein levels of Gls1 in the mitochondria of fibroblasts. Finally, to support a proof-ofconcept that Gls1 inhibition functions in the treatment of IPF by attenuating collagen deposition, the authors created Gls1 2/2 knockdown mice and demonstrated diminished profibrotic mediators, including reduced transcription of fibronectin, a-smooth muscle actin, and collagens, in mice exposed to bleomycin. The authors then used a known pharmaceutical inhibitor of Gls1, CB-839, in the TGF-b-exposed mouse lung fibroblasts and found selective inhibition of protein levels of Collagen I and Collagen III, but not a-smooth muscle actin or fibronectin. They also demonstrated accelerated collagen degradation in the CB-839-treated cells, which nicely supports their prior work indicating that Gls1 plays a role in collagen protein expression through collagen stabilization. In their last experiment, the authors sought to build upon the prophylactic or protective use of CB-839. They began treatment with CB-839 once daily for 2 weeks in bleomycin-exposed mice after Day 7 of bleomycin inoculation, and found decreased levels of hydroxyproline, improved histology, and reduced collagen deposition. They repeated this treatment strategy in mice exposed to adenovirus expressing active TGF-b1 and found a more modest improvement in pulmonary fibrosis assessed by histology and, unfortunately, little change in hydroxyproline levels.
Despite this compelling evidence, a continued healthy skepticism about extrapolating these data to success in clinical practice is warranted. Universally, there is still concern that the intratracheal bleomycin mouse model does not accurately represent the human IPF clinical and pathological phenotype, and many studies that showed efficacy in this model have failed to translate to clinical utility (9) (10) (11) . Additionally, both the bleomycin and TGF-b exposure-based studies seem to support the use of the inhibitor molecule as a prophylaxis against the development of pulmonary fibrosis rather than as a treatment for established fibrosis, based on initiation of the inhibitor at 1 week, when acute inflammation rather than established fibrosis is present (9, 12) . The TGF-b-induced fibrosis model also did not show as robust an attenuation of fibrosis formation after exposure to CB-839. Finally, not all components of the fibrotic milieu were attenuated by CB-839 treatment in these studies, which raises a question as to whether inhibition of collagen protein synthesis and stabilization is enough to prevent the clinical signs and symptoms of pulmonary fibrosis.
Liu and colleagues should be commended for the logical and thorough nature of their present and preceding studies of this novel glutaminolysis pathway and its role in lung fibrosis. It goes without saying that the medical community is in need of additional treatment options for IPF. Through their seminal work, the authors continue to build a robust argument for the use of Gls1 inhibitors as a potential therapeutic intervention to be tested in human clinical trials. n Author disclosures are available with the text of this article at www.atsjournals.org.
